Genomics

Executive Summary

Genomics, based in Cambridge, UK and founded in 1998, is a private company that has established itself as the industry leader in identifying an individual’s absolute risk of disease. The company’s platform is powered by one of the world’s largest and most unique genetic databases, enabling a wide range of stakeholders—including patients, healthcare providers, employers, pharma companies, and researchers—to make smarter decisions for longer, healthier lives. By focusing on absolute risk rather than relative risk, Genomics provides a more precise and actionable understanding of disease susceptibility, which is critical for preventive medicine and personalized healthcare. The company’s long-standing presence in the field and its proprietary database give it a significant competitive advantage in the rapidly growing genomics market. Looking ahead, Genomics is well-positioned to capitalize on the increasing demand for genetic risk assessment in both clinical and direct-to-consumer settings. The company’s platform has potential applications across multiple therapeutic areas, including cardiovascular disease, oncology, and metabolic disorders. As healthcare systems shift toward value-based care and preventive strategies, Genomics’ unique value proposition could drive widespread adoption. However, as a private company with limited public information, its near-term trajectory depends on strategic partnerships, product launches, and funding. The following catalysts are anticipated over the next 12–18 months.

Upcoming Catalysts (preview)

• Q4 2026Launch of population health screening product for common chronic diseases70% success
• Q3 2026Strategic partnership with a top-20 pharma company for drug target discovery using its database60% success
• Q2 2026Series C funding round to expand AI capabilities and enter new international markets50% success